RxDoctor Payments Data

Kenneth Olson, MD

Addiction Psychiatry · Bozeman, MTNPI 1407927510

Payments from drug & device makers

$2,518in general payments, 2019–2025

Across 147 payments — averaging $17.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$411
  • Teva Pharmaceuticals USA, Inc.$351
  • Sunovion Pharmaceuticals Inc.$340
  • Supernus Pharmaceuticals, Inc.$309
  • Neurocrine Biosciences, Inc.$255
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$121
  • plus $730 from 15 others

What the payments were for

  • Food & beverage$2,518100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few addiction psychiatry providers in Montanato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$69,813
Medicare patients
69
Services billed
691

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate15$117,692
BelsomraSuvorexant17$8,826
ZubsolvBuprenorphine Hcl/Naloxone Hcl12$7,084
Lisdexamfetamine Dimesylate15$4,628
VyvanseLisdexamfetamine Dimesylate11$4,441
Dextroamphetamine Sulfate ErDextroamphetamine Sulfate12$2,350
Dexmethylphenidate Hcl ErDexmethylphenidate Hcl28$2,236
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine74$2,233
Lamotrigine167$1,444
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine41$1,367
Atomoxetine Hcl35$1,280
Venlafaxine Hcl ErVenlafaxine Hcl80$1,237
Buspirone Hcl85$1,156
Oxcarbazepine17$971
Methylphenidate ErMethylphenidate Hcl18$928

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$255$117,69215 claims
Lilly USA, LLCOlanzapine$23$66543 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few addiction psychiatry providers in Montanaon file to place this against a meaningful peer group, so we don't.

Other addiction psychiatry in Bozeman

Where these figures come from

Is this you, or does something look wrong? →